Cypress Capital Group’s iShares Biotechnology ETF IBB Stock Holding History

Cypress Capital Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,498	Closed	-$434K	–	241
2018 Q4	$434K	Sell	4,498 -616	-12%	-$65.4K	0.1%	151
2018 Q3	$623K	Buy	5,114 +300	+6%	+$35.3K	0.12%	150
2018 Q2	$529K	Buy	4,814 +600	+14%	+$64.2K	0.11%	152
2018 Q1	$449K	Buy	+4,214	New	+$467K	0.09%	159
2016 Q4	–	Sell	-2,580	Closed	-$249K	–	187
2016 Q3	$249K	Buy	+2,580	New	+$245K	0.06%	162
2015 Q3	–	Sell	-1,920	Closed	-$236K	–	197
2015 Q2	$236K	Buy	+1,920	New	+$230K	0.05%	188

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return

Cypress Capital Group's IBB Position: Q1 2019 in Review

Cypress Capital Group sold out of iShares Biotechnology ETF (IBB) in Q1 2019, closing a stake of 4,498 shares — an estimated $434K sold.

Cypress Capital Group first reported a position in IBB in Q2 2015 and held it in 6 quarters. The position peaked at $623K in Q3 2018. 670 funds tracked by Wall St. Rank hold IBB as of Q1 2019.

Cypress Capital Group reported no remaining iShares Biotechnology ETF position as of Q1 2019 after selling out during the quarter.
Cypress Capital Group sold 4,498 iShares Biotechnology ETF shares in Q1 2019, an estimated $434K.
Cypress Capital Group first reported a position in iShares Biotechnology ETF in Q2 2015 and held it in 6 quarters.
Cypress Capital Group's iShares Biotechnology ETF position peaked at $623K in Q3 2018.
670 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2019.

Based on Cypress Capital Group's 13F filing for Q1 2019, filed 14 May 2019.